Air T is a holding company. Through its subsidiaries, the company operates the following industry segments: overnight air cargo, which operates in the air express delivery services industry; ground equipment sales, which manufactures and provides mobile deicers and other equipment products; ground support services, which provides ground support equipment maintenance and facilities maintenance services; commercial aircraft, engines and parts, which provides services including commercial aircraft disassembly/part-out services; and printing equipment and maintenance, which designs, manufactures and sells digital print production equipment and provides maintenance services to commercial customers.

Anika Therapeutics is joint preservation and regenerative therapies company. The company's Joint Pain Management Therapies product family includes MONOVISC, ORTHOVISC, CINGAL, and HYVISC, hyaluronic acid (HA)-based intraarticular injectable products. The company's Orthopedic Joint Preservation and Restoration Care products include HYALOFAST, TACTOSET, Arthrosurface's catalogue of over 150 partial and total joint surface implants and preservation solutions for the knee, shoulder, hip, ankle, wrist and toe and Parcus Medical's line of surgical implant and instrumentation solutions. The company's Other product family consists of HA-based products that do not fit into one of its other primary product categories.

Celldex Therapeutics is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has four drug candidates in clinical development, including CDX-1140, an agonist human monoclonal antibody targeted to CD40, a key activator of immune response; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3; varlilumab, an immune modulating antibody targeting CD27 designed to improve a patient's immune response; and CDX-301, a dendritic cell growth factor.

Elanco Animal Health is an animal health company. The company groups its products into four principal categories: Companion Animal (CA) Disease Prevention, which includes parasiticides and vaccine products for canines and felines; CA Therapeutics, which includes products for the treatment of pain, osteoarthritis, otitis, cardiovascular and dermatology indications in canines and felines; Food Animal (FA) Future Protein and Health, which includes vaccines, antibiotics, parasiticides and other products used in poultry and aquaculture production; and FA Ruminants and Swine, which includes vaccines, antibiotics, implants, parasiticides and other products used in ruminants and swine production.

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

Kodiak Sciences is a clinical stage biopharmaceutical company focusing on therapeutics to treat chronic, high-prevalence retinal diseases. The company's main product candidate is KSI-301, a biologic therapy built with the company's antibody biopolymer conjugate platform, which is designed to maintain drug levels in ocular tissues. KSI-301 is used to treat patients with wet age-related macular degeneration, diabetic retinopathy, including diabetic macular edema, and macular edema due to retinal vein occlusion. The company has applied its antibody biopolymer conjugate platform to develop additional product candidates beyond KSI-301, including KSI-501, its bispecific anti-IL-6/VEGF bioconjugate.